Published in final edited form as:

J Clin Densitom. 2020 ; 23(4): 685–689. doi:10.1016/j.jocd.2019.09.004.

Bone Shock Absorption in Pediatric Patients with Osteogenesis Imperfecta – A Pilot Study to Assess the Potential of this Technique to Detect Differences in Bone Fragility

McKenzie L. Nelson, BS¹, Cynthia Cox, BS², Lorena Altman, BRST², Jane Khoury, PhD³, Amit Bhattacharya, PhD², Halley Wasserman, MD, MSc, CCD^{1,4}

¹University of Cincinnati College of Medicine

²University of Cincinnati College of Medicine Department of Environmental Health

³Cincinnati Children's Hospital Division of Biostatistics and Engineering

⁴Cincinnati Children's Hospital Department of Endocrinology

Introduction

Inadequate bone mass acquisition during childhood is associated with an increased lifetime risk for fractures. Currently, dual energy x-ray absorptiometry (DXA) is used clinically to measure areal bone mineral density (aBMD) but is not sensitive enough to quantify risk of fragility fractures in children (1).

Osteogenesis imperfecta (OI) is most commonly due to mutations in collagen (*COL1A1* or *COL1A2*) that impairs triple helix formation, resulting in decreased bone mineralization. OI type 1 is the mildest form, generally presenting during childhood with recurrent fragility fractures. Treatment with bisphosphonate therapy has been shown to increase aBMD and reduce fractures but is generally reserved for those suffering multiple fractures per year (2). Clinical decision making on bisphosphonate use is often based on aBMD Z-score (2). Despite improvements in aBMD, fracture rates remain elevated indicating that there are other factors to consider in assessing skeletal integrity of children with primary forms of osteoporosis.

Bone Shock Absorption (BSA) is a technique that measures damping, the ability of bone to absorb external forces, dynamically (3). Higher damping indicates an increased resistance to fracture. BSA has been validated in postmenopausal women diagnosed with osteoporosis (by DXA), differentiating those with and without fractures. BSA has not previously been tested in young children but offers an alternative, non-invasive method to assess the skeletal integrity of children with bone disease. Here we report the use of the BSA technique in pre-pubertal children to gather preliminary data on its ability to discriminate the degree of bone fragility in those with OI compared to healthy children of similar age, sex, and race.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Patients and Methods

Participants

Children ages 5-18 years with genetically confirmed OI Type 1 were eligible for participation in this pilot study. Patients with OI were ineligible for participation if they had another neurological disorder, were unable to stand or walk for 10 minutes without discomfort or assistance, or had indwelling metal hardware. Three pre-pubertal children were enrolled, with cases 1 and 2 being siblings. Pertinent demographics and bone history are described in Table 1. For Case 1, bisphosphonate infusions were discontinued because of improvement in lumbar spine aBMD Z-score to -1.1 but were subsequently resumed due to ongoing vertebral compression fractures. For Case 2, bisphosphonate infusions were discontinued. For Case 3, bisphosphonate infusions have not been used.

Six healthy children of similar age and race to cases were included as controls. To participate, these control subjects also had to satisfy the same exclusion criteria as cases but also have no family history of bone disease. None of the controls had ever sustained a fracture except Case 8 (traumatic distal forearm fracture at 4y10m).

DXA

Subjects underwent DXA scans (Hologic) of the anterior-posterior lumbar spine. Height adjusted Z-scores were calculated using BMDCS reference data (4, 5).

BSA Testing

For each subject, low-mass accelerometers were attached at the lateral femoral condyle and tibial tuberosity to capture damping and resonance frequencies while minimizing the effect of soft tissue according to the technique previous described (6). Subjects tapped one heel on the force platform (Model OR6-7-1000, Advanced Mechanical Technology Inc. Watertown, MA) with a force used during normal walking at least five times for an average damping value. Accelerometers measure resonance frequency as force propagates up through the body and provides a frequency response function (FRF). Custom software was used to analyze FRFs and select crucial peaks to calculate damping.

Statistical Analysis

Due to sample size, non-parametric statistics were used for analysis. Specifically, Wilcoxon rank sum test was used to examine differences between OI and control subjects, using the mean of the repeated trials. A general linear model was used in order to incorporate repeated trials within subject to estimate the least-square mean and associated standard error for the figures.

Results

Statistical analysis indicated a significant difference between cases and controls at the right lateral femoral condyle ($p=0.04$). This trend seemed to be more evident in males than females (Fig. 1).

The two girls with OI were compared separately, as case 2 received bisphosphonate therapy whereas Case 3 had not. Case 2 currently has a higher aBMD Z-score than Case 3, but damping values are lower (Fig. 2).

For all subjects, no relationship was found between DXA aBMD Z-scores and damping measured by BSA (Fig. 3).

Figure 4 compares damping values reported here to available adolescent and adult data.

Discussion

DXA is an important tool for guiding the clinical diagnosis and management of osteoporosis in adults and children. However, there are limitations in its ability to fully assess bone fragility and the response of bone to mechanical loading. In children specifically, the ability of DXA to predict future fracture risk is limited. Pediatricians have few tools to assess response to bisphosphonate therapy in children with disorders of bone metabolism receiving this intervention as bone turnover markers are not routinely available for clinical use. Thus, additional measures to assess bone strength are greatly needed.

BSA has been proposed as an additional tool to predict fracture risk in adult women with osteoporosis (6). This pilot study demonstrates the practicality of BSA in pre-pubertal children. Based on previous populations tested (3,7), the damping values obtained in this age group appear to be valid. Figure 4 suggests a pattern of damping values declining with age, which may be due to differences in collagen to mineral ratios. The difference in ability to discriminate between the left and right leg may be due to handedness, as not all subjects were right-handed.

Results of our study are limited given its small sample size, however the cases studied were representative of typical children with OI Type 1. We found no relationship between aBMD Z-scores and damping, suggesting that BSA may provide additional unique information about bone health. As trabecular microarchitecture is critical in shock absorption, the lumbar spine scan site, a region of primarily trabecular bone, is ideal for comparison with damping. Trabecular bone is also present at metaphyses of long bones. Measurements of density and microarchitecture at these regions may show different correlations with damping providing a more complete picture of bone integrity. A larger study in pre-pubertal, healthy children is necessary to clarify our findings and determine the pattern of normal damping throughout childhood, creating a reference for future investigation.

Our data suggests that BSA may detect differences in children with genetic conditions of skeletal fragility, similar to findings in post-menopausal women (3). Bisphosphonate therapy normalized aBMD Z-score (Case 2), however damping was lower compared to Case 3 with a similar aBMD though no history of bisphosphonate exposure. This suggests that differences in bone integrity remain despite normal density. The small sample size in this study precludes the ability to detect statistically significant differences in damping and fracture rates between cases and controls and within bisphosphonate treated and untreated cases. Further research into BSA and other measures of bone's ability to resist fracture would

improve clinical treatment decisions, especially for children with clinically significant fragility fractures.

Acknowledgments

Funding: NIH grant T35DK060444 (P.I. Heubi).

BSA operations training and equipment: NIH grant 1R01ES024074-01: P.I. Bhattacharya/Watts, BSA Patent Serial No. 12/402,586.

References

1. Hernandez CJ, Beaupré GS, Carter DR. 2003 A theoretical analysis of the relative influences of peak BMD, age-related bone loss and menopause on the development of osteoporosis. *Osteoporos Int.* 14(10):843–7. [PubMed: 12904837]
2. Palomo T, Fassier F, Ouellet J, et al. 2015 Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: Skeletal findings during follow up throughout the growing years. *J Bone Miner Res.* 30(12):2150–7. [PubMed: 26059976]
3. Bhattacharya A, Watts NB, Dwivedi A, Shukla R, Mani A, Diab D. 2016 Combined measures of dynamic bone quality and postural balance - A fracture risk assessment approach in osteoporosis. *J Clin Densitom.* Apr-Jun;19(2):154–64. [PubMed: 25936482]
4. Kalkwarf HJ, Zemel BS, Yolton K, Heubi JE. 2013 Bone mineral content and density of the lumbar spine of infants and toddlers: influence of age, sex, race, growth, and human milk feeding. *J Bone Miner Res.* 28(1):206–212. [PubMed: 22887693]
5. Zemel BS, Kalkwarf HJ, Gilzanz V, et al. 2011 Revised Reference Curves for Bone Mineral Content and Areal Bone Mineral Density According to Age and Sex for Black and Non-Black Children: Results of the Bone Mineral Density in Childhood Study. *J Clin Endocrinol Metab.* 96(10): 3160–3169. [PubMed: 21917867]
6. Bhattacharya A, Watts N, Davis K, et al. 2010 Dynamic Bone Quality – A Non-invasive Measure of Bone's Biomechanical Property in Osteoporosis. *J Clin Densitom.* 4;13(2): 228–236. [PubMed: 20347363]
7. Bhattacharya A, Watts N, Gordon J, et al. 2007 Bone quantity and quality of youths working on a farm - A pilot study. *J. of Agromedicine.* 12(4): 27–38.
8. Huang S, Bhattacharya A. 1993 The effects of osteoarthritis on the biomechanical properties of the tibia. *Chinese J Med and Biol Eng.* 1993;13 (3):255–264
9. Bhattacharya A. A New Measure of Dynamic Bone Quality; Invited Keynote Seminar at the BME Seminar Series; Fall 2018; F. Joseph Halcomb, MD Department of Biomedical Engineering, University of Kentucky, Lexington, Ky: Nov 2, 2018

Figure 1:
Comparison of Group Mean Damping Value by Anatomical Site

Figure 2:
Comparison of Damping Values between Two Case Subjects; Case 2 Receives
Bisphosphonate Treatment, Case 3 does not

Figure 3:
Height Adjusted Lumbar Spine Z-Score vs within Subject Mean Right Lateral Femoral Condyle Damping

Figure 4:
Age and Disease Related Changes in Damping; Osteogenesis Imperfecta (OI) Type I
Diagnosed Genetically, Osteoporosis Diagnosed by DXA

Table 1:

Relevant Bone Data for Case Subjects

	Historical Data			Current data at time of BSA	
	Age/Race/Sex	Fracture History	Bisphosphonate History	Height/Weight	BMD Z-score ^L
Case 1	9y10m Caucasian M	Left tibia (<i>age 18m</i>) Right tibia (<i>age 18m</i>) Right tibia (<i>age 2y8m</i>) T7 (<i>age 7y6m</i>) T9-T11 (<i>age 9y3m</i>)	Pamidronate monthly (2y8m-3y8m) Zoledronic Acid every 6 months (9y7m – current)	135.7cm (48%) 45.9kg (97%)	–3.3 (6)
Case 2	7y11m Caucasian F	Right tibia (<i>age 7m</i>) Left tibia (<i>age 11m</i>) Left Ulna (<i>age 2y10m</i>)	Pamidronate monthly (1y3m – 2y6m)	122.2cm (16%) 27.7kg (6%)	+0.5
Case 3	7y7m Caucasian F	Left radius/ulna (<i>age 4y8m</i>) Right radius (<i>age 4y10m</i>) Left <i>radius</i> (<i>age 6y3m</i>)	Not Applicable	119.8cm (16%) 28.7kg (78%)	–0.9

^LLumbar Spine Height adjusted Z-score for aBMD (Kalkwarf et al, J Bone Miner Res. 28(1):206-212)